Smith & Nephew to acquire DFB dermatology subsidiary

Smith & Nephew plc (LSE:SN; NYSE:SNN) will acquire the Healthpoint Biotherapeutics subsidiary of DFB Pharmaceuticals Inc. (Fort Worth, Texas) for $782 million in cash. Smith & Nephew, which plans to i...